Form 4: Vertex Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer of Vertex Pharmaceuticals, sold 2,650 shares of common stock at $475.34 per share on February 27, 2025, according to a Form 4 filing.
Summary
- Edward Morrow Atkinson III, an executive at Vertex Pharmaceuticals, reported transactions involving the company's common stock.
- On February 26, 2025, Atkinson had 2,482 shares withheld for taxes at a price of $479.61.
- On February 27, 2025, Atkinson sold 2,650 shares at $475.34 per share.
- Following these transactions, Atkinson directly owns 19,352 shares of Vertex Pharmaceuticals common stock.
- The transactions were executed under a pre-arranged trading plan (Rule 10b5-1) established on February 22, 2024.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Executive stock transactions are a normal part of corporate governance. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of acting on non-public information.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, but the use of a 10b5-1 plan suggests it was pre-planned and not based on inside information.
Key Dates
| Date | Description |
|---|---|
| 02/22/2024 | Date of establishment of the Rule 10b5-1 trading plan |
| 02/26/2025 | Date of tax withholding of 2,482 shares |
| 02/27/2025 | Date of sale of 2,650 shares |
| 02/28/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.